open access

Vol 65, No 4 (2014)
Original papers
Published online: 2014-08-29
Submitted: 2014-08-29
Accepted: 2014-08-29
Get Citation

The effect of short-term combined treatment with simvastatin and ezetimibe on circulating adipokine levels in patients with isolated hypercholesterolemia

Robert Krysiak, Witold Żmuda, Bogdan Marek, Bogusław Okopień
DOI: 10.5603/EP.2014.0037
·
Endokrynologia Polska 2014;65(4):275-280.

open access

Vol 65, No 4 (2014)
Original papers
Published online: 2014-08-29
Submitted: 2014-08-29
Accepted: 2014-08-29

Abstract

Introduction: Although several studies have assessed plasma adipokines in patients treated with hypolipidemic agents, these studies have provided contrasting results.

Material and methods: This study included 19 high-risk patients with elevated total and LDL cholesterol levels treated with simvastatin (40 mg daily) and ezetimibe (10 mg daily). Plasma levels of leptin, adiponectin, visfatin, tumour necrosis factor-α, free fatty acids as well as C-reactive protein were measured before and after 30 days of treatment. High-risk hypercholesterolemic patients were compared with 17 age-, sex- and weight-matched healthy subjects who did not receive any treatment.

Results: Compared to the healthy subjects, hypercholesterolemic patients exhibited lower plasma levels of adiponectin, as well as higher plasma levels of the remaining adipokines. Administration of simvastatin and ezetimibe for 30 days reduced plasma levels of leptin, visfatin, TNF-α, as well as increased plasma levels of adiponectin. The treatment also reduced free fatty acids and C-reactive protein.

Conclusions: High-risk hypercholesterolemic patients with elevated cholesterol levels are characterised by abnormal production of adipose tissue hormones. Short-term treatment with simvastatin and ezetimibe partially restores adipokine production and inhibits low-grade inflammation. (Endokrynol Pol 2014; 65 (4): 275–280)

Abstract

Introduction: Although several studies have assessed plasma adipokines in patients treated with hypolipidemic agents, these studies have provided contrasting results.

Material and methods: This study included 19 high-risk patients with elevated total and LDL cholesterol levels treated with simvastatin (40 mg daily) and ezetimibe (10 mg daily). Plasma levels of leptin, adiponectin, visfatin, tumour necrosis factor-α, free fatty acids as well as C-reactive protein were measured before and after 30 days of treatment. High-risk hypercholesterolemic patients were compared with 17 age-, sex- and weight-matched healthy subjects who did not receive any treatment.

Results: Compared to the healthy subjects, hypercholesterolemic patients exhibited lower plasma levels of adiponectin, as well as higher plasma levels of the remaining adipokines. Administration of simvastatin and ezetimibe for 30 days reduced plasma levels of leptin, visfatin, TNF-α, as well as increased plasma levels of adiponectin. The treatment also reduced free fatty acids and C-reactive protein.

Conclusions: High-risk hypercholesterolemic patients with elevated cholesterol levels are characterised by abnormal production of adipose tissue hormones. Short-term treatment with simvastatin and ezetimibe partially restores adipokine production and inhibits low-grade inflammation. (Endokrynol Pol 2014; 65 (4): 275–280)

Get Citation

Keywords

simvastatin; ezetimibe; hypercholesterolemia; leptin; adiponectin; visfatin; tumour necrosis factor α (TNF-α)

About this article
Title

The effect of short-term combined treatment with simvastatin and ezetimibe on circulating adipokine levels in patients with isolated hypercholesterolemia

Journal

Endokrynologia Polska

Issue

Vol 65, No 4 (2014)

Pages

275-280

Published online

2014-08-29

DOI

10.5603/EP.2014.0037

Bibliographic record

Endokrynologia Polska 2014;65(4):275-280.

Keywords

simvastatin
ezetimibe
hypercholesterolemia
leptin
adiponectin
visfatin
tumour necrosis factor α (TNF-α)

Authors

Robert Krysiak
Witold Żmuda
Bogdan Marek
Bogusław Okopień

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl